BME vs BRK-B
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a Piotroski F-Score of 5/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a full bankruptcy risk assessment. Despite a high dividend yield of 7.43%, the unsustainable 162.83% payout ratio raises concerns about dividend continuity. Profitability metrics show mixed signals with a 100% gross margin but zero profit margin and negative ROE of -4.63%, suggesting underlying operational inefficiencies. The technical trend score of 10/100 indicates strong bearish momentum, further weakening the investment case.
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
Compare Another Pair
Related Comparisons
BME vs BRK-B: Head-to-Head Comparison
This page compares BlackRock Health Sciences Trust (BME) and Berkshire Hathaway Inc. (BRK-B) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.